Indications for: Aminocaproic Acid Injection
Bleeding associated with fibrinolysis.
4–5g (in 250mL of diluent) by IV infusion during the 1st hour, then 1g/hour (in 50mL of diluent) for 8 hours or until bleeding is controlled.
Aminocaproic Acid Injection Contraindications:
Active intravascular clotting process. Disseminated intravascular coagulation without concomitant heparin.
Aminocaproic Acid Injection Warnings/Precautions:
Upper urinary tract bleeding: not recommended. Cardiac, hepatic or renal disease. Risk of myopathy with long-term use; monitor creatine phosphokinase (CPK); discontinue if CPK rises. Avoid rapid IV administration. Neonates. Pregnancy (Cat.C). Nursing mothers.
Aminocaproic Acid Injection Classification:
Aminocaproic Acid Injection Interactions:
Avoid concomitant Factor IX complex or Anti-inhibitor Coagulant concentrates; may increase thrombosis risk.
Inj site reactions, bradycardia, hypotension, GI upset, edema, headache, malaise, CNS effects, thrombosis, others; rare: myopathy.
Tabs—100; Oral soln—473mL; Inj—contact supplier